ALBT

Avalon GloboCare Corp. operates as a clinical-stage biotechnology company focused on developing cell-based technologies and treatments. Headquartered in Freehold, New Jersey, the company concentrates on cell-based immunotherapy, exosome technology, and regenerative medicine through its proprietary platforms. Avalon's business model centers on advancing precision diagnostics and therapeutic candidates targeting cancer, infectious diseases, and age-related chronic conditions. The company develops its AVA Exosome Platform for disease detection and monitoring, alongside immune cell banking and manufacturing capabilities through its subsidiary GenExosome Technologies. Avalon maintains strategic partnerships with academic institutions and research organizations to advance its clinical pipeline, which includes programs in ovarian cancer detection and immuno-oncology treatments. The company operates laboratory facilities in the United States and has established collaborations in Asia to expand its manufacturing and clinical development footprint. Recent developments include advancing its exosome-based diagnostic technologies and expanding its cell therapy manufacturing capabilities. Avalon also pursues strategic investments and partnerships in complementary healthcare technology sectors. As a development-stage entity, the company allocates resources toward research and development activities, clinical trials, and regulatory pathway advancement for its product candidates. The company trades on the NASDAQ Capital Market and continues to evolve its pipeline through internal development and collaborative arrangements with research institutions.